Dante J. Merlino

ORCID: 0000-0001-9998-0579
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Head and Neck Cancer Studies
  • Tracheal and airway disorders
  • Cancer Diagnosis and Treatment
  • Cleft Lip and Palate Research
  • Cancer Research and Treatments
  • Endoplasmic Reticulum Stress and Disease
  • Genetic factors in colorectal cancer
  • Cervical Cancer and HPV Research
  • Craniofacial Disorders and Treatments
  • Phosphodiesterase function and regulation
  • Voice and Speech Disorders
  • Cancer, Hypoxia, and Metabolism
  • Pharmacological Effects of Natural Compounds
  • Plasma Applications and Diagnostics
  • Multiple and Secondary Primary Cancers
  • Glycosylation and Glycoproteins Research
  • Digital Imaging in Medicine
  • Interpreting and Communication in Healthcare
  • Sinusitis and nasal conditions
  • Galectins and Cancer Biology
  • Cancer Immunotherapy and Biomarkers
  • Thyroid and Parathyroid Surgery
  • Metastasis and carcinoma case studies
  • Hedgehog Signaling Pathway Studies
  • Salivary Gland Tumors Diagnosis and Treatment

Mayo Clinic
2022-2024

Mayo Clinic in Arizona
2022-2024

University of Minnesota Rochester
2022-2023

WinnMed
2022

Thomas Jefferson University
2014-2020

Io Therapeutics (United States)
2019

Immunogenic cell death is characterized by the emission of danger signals that facilitate activation an adaptive immune response against dead-cell antigens. In case cancer therapy, tumor cells undergoing immunogenic promote cancer-specific immunity. Identification, characterization, and optimization stimuli induce has tremendous potential to improve outcomes therapy. this study, we show non-thermal, atmospheric pressure plasma can be operated in animal model colorectal cancer.

10.1080/2162402x.2018.1484978 article EN OncoImmunology 2018-06-12

Abstract Background/Objectives: The uroguanylin-GUCY2C gut–brain axis has emerged as one component regulating feeding, energy homeostasis, body mass and metabolism. Here, we explore a role for this in mechanisms underlying diet-induced obesity (DIO). Subjects/Methods: Intestinal uroguanylin expression secretion, hypothalamic GUCY2C anorexigenic signaling, were quantified mice on high-calorie diets 14 weeks. of endoplasmic reticulum (ER) stress suppressing DIO was explored using tunicamycin,...

10.1038/nutd.2016.18 article EN cc-by Nutrition and Diabetes 2016-05-23

PD-1 blockade represents a promising treatment in patients with head and neck squamous cell carcinoma (HNSCC). We analyzed results of neoadjuvant randomized window-of-opportunity trial nivolumab plus/minus tadalafil to investigate whether immunotherapy-mediated effects vary by site involvement (primary tumor, lymph nodes) determine how radiographic tumor shrinkage correlates pathologic effect. Forty-four enrolled NCT03238365 were treated 240 mg intravenously on days 1 15 or without oral...

10.3389/fonc.2020.566315 article EN cc-by Frontiers in Oncology 2020-12-02

Enterotoxigenic Escherichia coli (ETEC) causes ∼20% of the acute infectious diarrhea (AID) episodes worldwide, often by producing heat-stable enterotoxins (STs), which are peptides structurally homologous to paracrine hormones intestinal guanylate cyclase C (GUCY2C) receptor. While molecular mechanisms mediating ST-induced secretion have been defined, advancements in therapeutics hampered for decades paucity disease models that integrate and functional endpoints amenable high-throughput...

10.1128/iai.00639-16 article EN Infection and Immunity 2016-08-02

// Glen P. Marszalowicz 1 , Adam E. Snook 2 Michael S. Magee Dante Merlino Lisa D. Berman-Booty 3 and Scott A. Waldman School of Biomedical Engineering, Science, Health Systems, Drexel University, Philadelphia, PA, USA Department Pharmacology Experimental Therapeutics, Thomas Jefferson Cancer Biology, Correspondence: Waldman, email: Keywords : GUCY2C, immunotoxin, therapeutic targeting, metastatic colorectal cancer Received August 14, 2014 Accepted September 07, Published 08, Abstract The...

10.18632/oncotarget.2455 article EN Oncotarget 2014-09-08
G. Todd Milne Peter Sandner Kathleen Lincoln Paul C. Harrison Hongxing Chen and 95 more Hong Wang Holly Clifford Hu Sheng Qian Diane Wong Chris Sarko Ryan M. Fryer Jeremy G. Richman Glenn A. Reinhart Carine Boustany Steven S. Pullen Henriette Andresen Lise Román Moltzau Alessandro Cataliotti Finn Olav Levy Robert Łukowski Sandra Frankenreiter Andreas Friebe Timothy D. Calamaras R. Baumgärtner Angela McLaughlin Mark Aronovitz Wendy Baur Guangrong Wang Navin K. Kapur Richard H. Karas Robert M. Blanton Stefan W. Hell Scott A. Waldman Jieru E. Lin Francheska Colón‐González Gilbert W. Kim Erik Blomain Dante J. Merlino Adam E. Snook Jeanette Erdmann Jana Wobst Thorsten Kessler Heribert Schunkert Ulrich Walter Oliver Pagel Elena Walter Stepan Gambaryan Albert Smolenski Kerstin Jurk René P. Zahedi James R. Klinger Raymond L. Benza Paul A. Corris David Langleben Robert Naeije Gérald Simonneau Christian Meier Pablo Colorado Mi Kyung Chang Dennis Busse Marius M. Hoeper Jaime L. Masferrer Sarah Jacobson Guang Liu Renee Sarno Sylvie G. Bernier Ping Zhang G. Todd Milne Roger Flores‐Costa Mark G. Currie K. Hall Dorit Möhrle Katrin Reimann Steffen Wolter Markus Wolters Evanthia Mergia Nicole Eichert H Geisler Peter Ruth Andreas Friebe Robert Feil Ulrike Zimmermann Doris Koesling Marlies Knipper Lukas Rüttiger Yasutake Tanaka Atsuko Okamoto Takashi Nojiri Motofumi Kumazoe Takeshi Tokudome Koichi Miura Jun Hino Hiroshi Hosoda Mikiya Miyazato Kenji Kangawa Vikas Kapil Amrita Ahluwalia Nazareno Paolocci Philip Eaton James C. Campbell

The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signalling pathway plays a fundamental role in modulating diverse physiological processes including blood flow, fibrosis, inflammation, and metabolism.sGC stimulators are small-molecule, heme-dependent agonists of sGC that synergize with enhance endogenous NO signaling.As such, may provide therapeutic benefits both diseases associated impaired signaling where stimulation this will restore functional...

10.1186/s40360-017-0170-5 article EN cc-by BMC Pharmacology and Toxicology 2017-10-01

Objectives To measure baseline human papillomavirus (HPV) vaccination rates among tertiary and community‐based Otolaryngology – Head Neck Surgery (Oto‐HNS) clinic patients to determine risk factors for under‐vaccination. Methods Retrospective chart review of aged 9 26 years presenting an Oto‐HNS from 2017 2019. Patients were considered complete HPV if they received two doses vaccine with the first dose before age 15 or three otherwise. Results 8,532 unique met criteria. At index visit, 3,110...

10.1002/lary.30130 article EN The Laryngoscope 2022-04-02

Objective To describe the rare process of osteolytic labyrinthitis, previously referred to as labyrinthine sequestrum, which involves progressive obliteration bony and membranous labyrinth with eventual supplantation soft tissue and, in some cases, sequestrum. Patients Three patients diverse presentations labyrinthitis from two tertiary care academic medical centers. Intervention(s) Case series report analyzing relevant clinical, radiologic, pathologic, surgical data on our comparing these...

10.1097/mao.0000000000004193 article EN Otology & Neurotology 2024-05-10

Objective The purpose of this study was to evaluate the performance advanced large language models from OpenAI (GPT‐3.5 and GPT‐4), Google (PaLM2 MedPaLM), an open source model Meta (Llama3:70b) in answering clinical test multiple choice questions field otolaryngology—head neck surgery. Methods A dataset 4566 otolaryngology used; each provided a standardized prompt followed by question. One hundred that were answered incorrectly all further interrogated gain insight into causes incorrect...

10.1002/lary.31781 article EN The Laryngoscope 2024-09-21

Abstract Disclosure: K.N. Rachmasari: None. A. Osman: D. Toro Tobon: S.B. Lund: D.J. Merlino: A.R. Hsu: M.M. Ryder: Background: In low-risk papillary thyroid cancer (PTC), radioactive iodine (RAI) remnant ablation has shown no impact on disease recurrence rates, which are overall low. The role of adjuvant RAI in intermediate risk (i.e. T3, N1) remains unproven with randomized clinical trials to objectively assess efficacy. Thus, our institution, its use is highly heterogenous. We...

10.1210/jendso/bvae163.1946 article EN cc-by-nc-nd Journal of the Endocrine Society 2024-10-01
Coming Soon ...